Europe
Biopharma and life sciences companies bolster their executive ranks and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
According to a study published in Nature Communications on August 11, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.
While Russian President Vladimir Putin expressed confidence in the preventative medication against the novel coronavirus, scientists from across the globe expressed concern over the lack of available data.
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Olorofim is in a Phase IIb study that focuses on rare and resistant life-threatening invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis and coccidioidomycosis.
Celleron Therapeutics signed a licensing agreement with Roche for the worldwide rights to cancer drug emactuzumab, a monoclonal antibody directed against colony-stimulating factor 1 (CSF-1R) expressed on macrophages.
The government of Russia has approved a vaccine for COVID-19, marking the first preventative treatment for the novel coronavirus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
PRESS RELEASES